title: Prolonged hypocalcemia following denosumab therapy in metastatic hormone refractory prostate cancer.
abstract: Prostate cancer is a leading cause of cancer death, frequently associated with widespread bone metastases. We report two cases of hypocalcemia following the first dose of denosumab in metastatic hormone refractory prostate cancer, the first case requiring 26 days of intravenous calcium therapy. This is the first report of prolonged hypocalcemia following denosumab in a patient with normal renal function.
authors.affiliation: Department of Endocrinology, Monash Health, Monash Medical Centre, Clayton, Australia. fran.milat@princehenrys.org
authors.forename: F
authors.initials: F
authors.lastname: Milat
authors.forename: S
authors.initials: S
authors.lastname: Goh
authors.forename: L U
authors.initials: LU
authors.lastname: Gani
authors.forename: C
authors.initials: C
authors.lastname: Suriadi
authors.forename: M T
authors.initials: MT
authors.lastname: Gillespie
authors.forename: P J
authors.initials: PJ
authors.lastname: Fuller
authors.forename: H J
authors.initials: HJ
authors.lastname: Teede
authors.forename: A H
authors.initials: AH
authors.lastname: Strickland
authors.forename: C A
authors.initials: CA
authors.lastname: Allan
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D000069448:Denosumab; D006801:Humans; D006996:Hypocalcemia / Q000139:chemically induced*; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D000069448:Denosumab